<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1583">
  <stage>Registered</stage>
  <submitdate>1/06/2007</submitdate>
  <approvaldate>1/06/2007</approvaldate>
  <nctid>NCT00482664</nctid>
  <trial_identification>
    <studytitle>The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.</studytitle>
    <scientifictitle>A Phase 2a Multi-Centre, Double Blind, Placebo Controlled Cross-Over Trial To Investigate The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women Diagnosed With Female Sexual Arousal Disorder (FSAD).</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>A5051017</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Sexual Dysfunction, Physiological</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Other reproductive health and childbirth disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - CP-866,087
Treatment: drugs - CP-866,087
Treatment: drugs - CP-866,087
Treatment: drugs - Placebo

Experimental: 1 mg - 

Experimental: 10 mg - 

Experimental: 3 mg - 

Placebo Comparator: Placebo - 


Treatment: drugs: CP-866,087
Tablets for oral administration

Treatment: drugs: CP-866,087
Tablets for oral administration

Treatment: drugs: CP-866,087
Tablets for oral administration

Treatment: drugs: Placebo
Tablets for oral administration

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Diary events, including Satisfactory Sexual Experiences (SSEs) over 6 weeks.</outcome>
      <timepoint>6 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Score in Abbreviated Sexual Function Questionnaire after 6 weeks of treatment.</outcome>
      <timepoint>6 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Exit interview at end of study. Meaningful Benefit Question at end of study.</outcome>
      <timepoint>End of study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Measure of Female Sexual Distress questionnaire after 6 weeks of treatment.</outcome>
      <timepoint>6 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  healthy pre-menopausal women

          -  primary female sexual arousal disorder causing distress

          -  on stable use of oral contraceptives</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  any other significant disease causing Female Sexual Dysfunction including psychiatric
             disease

          -  subjects on drugs known to cause Female Sexual Dysfunction

          -  subjects who have given birth in the last 12 months or who are planning to become
             pregnant during the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>84</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,WA</recruitmentstate>
    <hospital>Pfizer Investigational Site - Dulwich</hospital>
    <hospital>Pfizer Investigational Site - Nedlands</hospital>
    <postcode>5065 - Dulwich</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aarhus C</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Kobenhavn OE</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Odense C</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Kwa-Zulu Natal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Pretoria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Lund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Skovde</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>CP-866,087 is a non-hormonal compound, acting on the central nervous system, which has been
      shown in animal models to restore sexual function.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00482664</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>